RADNOR, Pa., Jan. 13, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 10, 202 ...

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk. ...

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=121992&from=4CLASS PERIOD: Februar ...

NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ps ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=121482&from=4CLASS PERIOD: February ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) investors of a class action representing investors that bought securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period"). Cassava investors have until February 10, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney ...

Financial Position - Unaudited cash and cash equivalents balance as of December 31, 2024 was approximately $128.6 million[4] Workforce Reduction - The company reduced its workforce by 10 employees, a reduction of 33%[7] - Estimated one-time costs of approximately $0.4 million related to severance payments for the workforce reduction[8] - Workforce reduction expected to be completed, and associated costs incurred, during the first quarter of 2025[8] Clinical Trials and Study Results - Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet prespecified co-primary endpoints[6] - The company decided to discontinue its Phase 3 ReFocus-ALZ study and its open-label extension study[6] - The company plans to share detailed study results at a future medical meeting[10] Forward-Looking Statements and Risks - Forward-looking statements include risks related to clinical study timelines, unexpected costs, and drug development uncertainties[11] Regulatory and Reporting - The company's press release dated January 7, 2025, is attached as Exhibit 99.1[12] - The report is signed by Eric J. Schoen, Chief Financial Officer, on January 7, 2025[15]

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment including a workforce reduction of approximately 33% Approximately $128.6 million cash and cash equivalents at December 31, 2024 (unaudited) AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=120897&from=3 CLASS PERIOD: ...

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/psl ...